EFPIA Calls On Drug Firms To Embrace Multi HTA Early Dialogue Scheme
This article was originally published in The Pink Sheet Daily
EFPIA is calling on its members to sign up to the European Commission’s multi HTA early dialogue initiative to harmonize some significant aspects of European reimbursement.
You may also be interested in...
Despite Lilly's decision not to make an indirect comparison its chosen comparator, AstraZeneca’s Brilinta, NICE agrees that Lilly's Efient is cost-effective and sometimes clinically superior to standard care.
While EU regulators and HTA bodies are coming together on major drug development criteria, differing standard care regimes across the 28 European Union member states makes real harmonization seem far off.
Agreement between Europe’s regulators and HTA bodies to develop collaborative approach does not yet address fundamental issues, such as standardization of comparator selection.